Abstract

The article discusses umbrella brands in the pharmaceutical sector. It is aimed at determining the place of umbrella branding in the Polish pharma law. By comparing the functions of brands and trademarks, the relationship between a typically marketing issue of umbrella brands and the provisions of the industrial property and fair competition laws currently in force in Poland has been presented.

It also presents the rules for denomination and designation of medicaments, medicinal products, dietary supplements, cosmetics and methods of classifying borderline products.

It outlines the marketing and legal benefits as well as threats connected with umbrella branding. Therefore, the aim of the article is to outline the rule, limits and consequences of using umbrella brands in the pharma sector both for consumers as well as brand managers.